参考文献/References:
[1] Reya T,Morrison SJ,Clarke MF,et al.Stem cells,cancer,and cancer stem cells[J].Nature,2001,414:105-111.
[2] Rajaraman R,Rajaraman MM,Rajaraman SR,et al.Neosis-a paradigm of self-renewal in cancer[J].Cell Biol Int,2005,29:1084-1097.
[3] 吴昭利,唐 星,李仁廷,等.培元抗癌汤加减对晚期结肠癌脾肾亏虚证患者血浆VEGF、CA724、TGF-β1及肠黏膜屏障功能的影响[J].陕西中医,2021,42(3):315-318.
[4] 丁 萍,鲁治文,王维民,等.康艾注射液联合卡培他滨及奥沙利铂治疗晚期结肠癌临床观察[J].陕西中医,2017,38(3):351-352.
[5] Thill M,Berna MJ,Grierson R,et al.Expression of CD133 and other putative stem cell markers in uveal melanoma[J].Melanoma Res,2011,21(5):405-416.
[6] Choijamts B,Jimi S,Kondo T,et al.CD133+ cancer stem cell-like cells derived from uterine carcinosarcoma(malignant mixed Mullerian tumor)[J].Stem Cells,2011,29(10):1485-1495.
[7] Dalerba P,Dylla SJ,Park IK,et al.Phenotypic characterization of human colorectal cancer stem cells [J].Proc Natl Acad Sci USA,2007,104(24):10158-10163.
[8] 石 芳,王 妍.肿瘤细胞与CD133+细胞数检测对恶性胸腔积液患者病情与治疗效果的预测价值[J].陕西医学杂志,2018,47(4):433-435.
[9] 王勇文,张 晋,冯 钢,等.CD133在食管鳞状细胞癌中的表达及临床意义[J].陕西医学杂志,2014,43(11):1464-1466.
[10] 黄毓婧,何爱娜,姚 阳,等.CD133作为肿瘤干细胞标志物的研究进展[J].癌症进展,2012,10(5):462-465.
[11] 李 健,周 峥,熊立新,等.CD44和CD133在慢性乙肝和肝细胞癌患者组织中的表达及其临床意义[J].现代肿瘤医学,2020,28(22):3946-3951.
[12] 林伟国,程变巧,朱 琪,等.瘤干细胞标志物CD133、CD90、CD44、ALDH1的表达与肝癌预后、代谢指标间的关系[J].福建医药杂志,2016,38(1):59-61.
[13] Tsai LL,Yu CC,Chang YC,et al.Markedly increased OCT4 and Nanog expression correlates with cisplatin resistance in oral squamous cell carcinoma[J].J Oral Pathol Med,2011,40(8):621-628.
[14] 王 飙.OCT4B1在乳腺癌组织中的表达及意义[J].陕西医学杂志,2011,40(12):1638-1639.
[15] Wu CL,Shieh GS,Chang CC,et al.Tumor-selective replication of an oncolytic adenovirus carrying OCT-3/4 response elements in murine metastatic bladder cancer models[J].Clin Cancer Res,2008,14:1228-1238.
[16] 钟 振,刘益飞,刘俊华.FOXO3基因在癌症中的研究进展[J].中国肿瘤外科杂志,2013,5(3):184-186.
[17] 陈 灿,张艳玲,刘小庆,等.miR-182对直肠癌细胞增殖、侵袭及Foxo3a/Wnt/β-catenin通路的调节作用[J].实用肿瘤学杂志,2020,34(4):328-333.
[18] 周乃强,姚杨玲,黄坚毅,等.FOXO3a蛋白对脑缺血损伤大鼠细胞自噬的影响研究[J].中西医结合心脑血管病杂志,2020,18(15):2422-2426.
[19] 张孝丽,车立群,吴红敬,等.FOXO3a通过PI3K/AKT信号通路介导炎症因子TNF-α抑制滋养细胞的增殖、侵袭及促进细胞发生凋亡[J].免疫学杂志,2020,36(6):482-489.
[20] 蒋国红,张 骏,王长明,等.转录因子FoxO3a对PC12细胞朊蛋白管家基因表达调控的影响[J].中国老年学杂志,2020,40(6):1305-1308.
相似文献/References:
[1]王 雄,张月飞,赵东雄,等.初诊结肠癌患者血小板相关指标与临床分期关系分析[J].陕西医学杂志,2019,(12):1676.
[2]龚 磊,吕真冰,喻 晶,等.SIRT1、Phospho-SIRT1在结肠癌组织中的表达及临床意义*[J].陕西医学杂志,2020,49(3):274.
GONG Lei,LV Zhenbing,YU Jing,et al.Expression and clinical significance of SIRT1 and Phospho-SIRT1 in colon cancer tissues[J].,2020,49(9):274.
[3]顾 勇,杨 艳,符 翠,等.白藜芦醇对结肠癌恶性生物学行为的抑制作用研究[J].陕西医学杂志,2021,50(9):1072.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.008]
GU Yong,YANG Yan,FU Cui,et al.Inhibitory effect of resveratrol on malignant biological behavior of colon cancer[J].,2021,50(9):1072.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.008]
[4]余 亮,郭 建,周国强,等.结肠癌患者血清微小RNA-193a-5p和微小RNA-139-5p表达检测及其对预后的影响[J].陕西医学杂志,2023,52(6):745.[doi:DOI:10.3969/j.issn.1000-7377.2023.06.024]
YU Liang,GUO Jian,ZHOU Guoqiang,et al.Expression of serum miR-193a-5p and miRNA-139-5p in patients with colon cancer and their effects on prognosis[J].,2023,52(9):745.[doi:DOI:10.3969/j.issn.1000-7377.2023.06.024]
[5]徐 敏,王彦舟,张 华.全身炎性反应指数联合控制营养状况评分对结肠癌患者预后的预测价值[J].陕西医学杂志,2023,52(11):1558.[doi:DOI:10.3969/j.issn.1000-7377.2023.11.023]
XU Min,WANG Yanzhou,ZHANG Hua.Predictive value of SIRI combined with CONUT score in prognosis of patients with colon cancer[J].,2023,52(9):1558.[doi:DOI:10.3969/j.issn.1000-7377.2023.11.023]
[6]王瑜崴,李 濛,康 博,等.结肠癌组织微小RNA-3607-3p、细胞周期蛋白E2表达及其与患者术后5年预后关系研究[J].陕西医学杂志,2024,(8):1124.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.026]
WANG Yuwei,LI Meng,KANG Bo,et al.Expression of microRNA-3607-3p and cyclin E2 in colon cancer tissues and their relationship with 5-year prognosis of patients after surgery[J].,2024,(9):1124.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.026]
[7]谭 蕊,李 论,罗 登.飞燕草素调控RhoA/ROCK信号通路对结肠癌细胞生物学行为及血管生成拟态形成的影响[J].陕西医学杂志,2024,(11):1468.[doi:DOI:10.3969/j.issn.1000-7377.2024.11.006]
TAN Rui,LI Lun,LUO Deng.Effects of delphinidin on the biological behavior and vasculogenic mimicry formation of colon cancer cells by regulating the RhoA/ROCK signaling pathway[J].,2024,(9):1468.[doi:DOI:10.3969/j.issn.1000-7377.2024.11.006]